View older revisions Content changed at 2026-10-12, 1405/07/20

Protocol summary

Study aim
To evaluate the safety and efficacy of resveratrol as an adjunctive treatment in hospitalized COVID-19 patients
Design
Randomized controlled clinical trial with parallel assignment
Settings and conduct
This study will be conducted at Razi Hospital, Ahvaz, Iran, from July to August 2020. Hospitalized patients with RT-PCR-confirmed COVID-19 will be assessed according to the inclusion and exclusion criteria and will then be randomly allocated to the intervention or control group
Participants/Inclusion and exclusion criteria
Participants: Adult hospitalized patients with RT-PCR-confirmed COVID-19 who require continuous oxygen therapy and have unilateral or bilateral pulmonary involvement. Inclusion criteria: Age ≥18 years, RT-PCR-confirmed COVID-19, hospitalization, requirement for continuous oxygen therapy, SpO₂ <93%, and unilateral or bilateral pulmonary involvement. Exclusion criteria: Renal failure, neurological disorders, and known allergy or hypersensitivity to resveratrol.
Intervention groups
Intervention group: Resveratrol 500 mg three times daily (TDS), in addition to standard COVID-19 care. Control group: Patients will receive standard COVID-19 treatment together with a placebo capsule identical in appearance to the resveratrol capsule
Main outcome variables
Length of hospital stay, measured from hospital admission to discharge

General information

Reason for update
This update is being made to correct and complete the information registered in the IRCT and to align the study protocol details with the final study information. Since this clinical trial was conducted during the early stages of the COVID-19 pandemic and under the specific circumstances of that period, some study details were initially registered based on the information and conditions available at that time. Following completion of the study and finalization of the study information, the details regarding the intervention, control group, eligibility criteria, study outcomes, and other methodological characteristics are being reviewed and updated. This update is intended to improve the accuracy, transparency, and consistency of the registered information in relation to the study conducted.
Acronym
IRCT registration information
IRCT registration number: IRCT20200112046089N1
Registration date: 2020-06-25, 1399/04/05
Registration timing: registered_while_recruiting

Last update: 2026-10-12, 1405/07/20
Update count: 1
Registration date
2020-06-25, 1399/04/05
Registrant information
Name
Arash Alghasi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 61 3374 3289
Email address
arashalqasi@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-06-14, 1399/03/25
Expected recruitment end date
2020-07-15, 1399/04/25
Actual recruitment start date
2020-06-14, 1399/03/25
Actual recruitment end date
2020-09-15, 1399/06/25
Trial completion date
empty
Scientific title
Evaluating the Safety and Efficacy of Resveratrol as an Adjunctive Treatment in Hospitalized COVID-19 Patients: A Randomized Controlled Trial
Public title
Resveratrol as an Adjunctive Treatment in Hospitalized COVID-19 Patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age ≥18 years RT-PCR-confirmed COVID-19 Hospitalization due to COVID-19 Requirement for continuous oxygen therapy Arterial oxygen saturation (SpO₂) <93% Unilateral or bilateral pulmonary involvement Hospitalization within 48 hours of symptom onset
Exclusion criteria:
Renal failure Neurological disorders Known allergy or hypersensitivity to resveratrol
Age
From 18 years old
Gender
Both
Phase
N/A
Groups that have been masked
  • Participant
  • Outcome assessor
Sample size
Target sample size: 60
Actual sample size reached: 44
Randomization (investigator's opinion)
Randomized
Randomization description
Eligible participants will be randomly allocated to either the intervention or control group using block randomization with blocks of 6 participants. The randomization sequence will be generated using WinPepi software, version 11.0. Each participant will be assigned a unique code (Uni Code) to maintain allocation concealment. Following randomization, participants will be allocated to either the resveratrol intervention group or the control group.
Blinding (investigator's opinion)
Double blinded
Blinding description
Participants and outcome assessors were blinded to the group allocation. To maintain blinding of the participants, the control group received a placebo capsule identical in appearance to the resveratrol capsule.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Ahvaz University of Medical Sciences
Street address
Golestan highway
City
Ahvaz
Province
Khouzestan
Postal code
15794-61357
Approval date
2020-05-16, 1399/02/27
Ethics committee reference number
IR.AJUMS.REC.1399.175

Health conditions studied

1

Description of health condition studied
COVID19
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified

Primary outcomes

1

Description
Length of hospital stay
Timepoint
From hospital admission until hospital discharge
Method of measurement
The length of hospital stay will be calculated as the duration from hospital admission to hospital discharge

Secondary outcomes

1

Description
Requirement for ventilatory support
Timepoint
During hospitalization
Method of measurement
The requirement for ventilatory support will be assessed based on the patient's clinical condition during hospitalization

2

Description
In-hospital mortality
Timepoint
During hospitalization
Method of measurement
Mortality will be assessed by recording the patient's survival or death during hospitalization

3

Description
C-reactive protein (CRP) level
Timepoint
Before and after the intervention
Method of measurement
CRP will be measured using peripheral blood samples collected before and after the intervention

4

Description
White blood cell count (WBC)
Timepoint
Before and after the intervention
Method of measurement
WBC will be measured using peripheral blood samples collected before and after the intervention

5

Description
Neutrophil count
Timepoint
Before and after the intervention
Method of measurement
Neutrophil count will be measured using peripheral blood samples collected before and after the intervention.

6

Description
Lymphocyte count
Timepoint
Before and after the intervention
Method of measurement
Lymphocyte count will be measured using peripheral blood samples collected before and after the intervention

7

Description
Lactate dehydrogenase (LDH) level
Timepoint
Before and after the intervention
Method of measurement
LDH will be measured using peripheral blood samples collected before and after the intervention

8

Description
Serum creatinine level
Timepoint
Daily during the study
Method of measurement
Serum creatinine will be assessed using peripheral blood samples and monitored daily for safety assessment

9

Description
Alanine aminotransferase (ALT) level
Timepoint
Daily during the study
Method of measurement
ALT will be assessed as part of liver function tests (LFTs) and monitored daily for safety assessment

10

Description
PRIEST score
Timepoint
Before and after the intervention
Method of measurement
The PRIEST score will be assessed according to the study protocol

Intervention groups

1

Description
Resveratrol 500 mg three times daily (TDS) in addition to standard COVID-19 care.
Category
Treatment - Drugs

2

Description
Placebo capsule resembling resveratrol in appearance, in addition to standard care for COVID-19
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Razi hospital
Full name of responsible person
Arash Alghasi
Street address
Razi hospital, Felestin boulevard, Amanieh
City
Ahvaz
Province
Khouzestan
Postal code
6155819953
Phone
+98 61 3555 0592
Email
arashalqasi@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Mohamad Badavi
Street address
Vice Chancellor of Research and Technology; Main building of Ahvaz University of Medical Science, Golestan highway
City
Ahvaz
Province
Khouzestan
Postal code
6135539345
Phone
+98 61 3311 3815
Email
Badavi-m@ajums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ahvaz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Arash Alghasi
Position
Assistant Professor of Pediatric Hematology and Oncology
Latest degree
Subspecialist
Other areas of specialty/work
Pediatric Hematology and Oncology
Street address
Ahvaz Shahid Baghaei 2 hospital; Golestan highway
City
Ahvaz
Province
Khouzestan
Postal code
6135539345
Phone
+98 61 3374 3289
Email
alghasi-a@ajums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Mohammad Reza Mahmoudian-Sani
Position
Assistant Professor of Molecular Medicine School of Medicine
Latest degree
Ph.D.
Other areas of specialty/work
Molecular Medicine
Street address
Ahvaz Shahid Baghaei 2 hospital; Golestan highway
City
Ahvaz
Province
Khouzestan
Postal code
6135539345
Phone
+98 61 3374 3289
Email
mohamadsani495@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Arash Alghasi
Position
Assistant Professor of Pediatric Hematology and Oncology Department of Pediatrics, School of Medicin
Latest degree
Subspecialist
Other areas of specialty/work
Pediatric Hematology and Oncology
Street address
Ahvaz Shahid Baghaei 2 hospital; Golestan highway
City
Ahvaz
Province
Khouzestan
Postal code
6135539345
Phone
+98 61 3374 3289
Email
alghasi-a@ajums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...